Degradation of apolipoprotein B-100 of human plasma low density lipoproteins by tissue and plasma kallikreins.

Abstract

Human plasma low density lipoproteins (LDL) contain one major apoprotein of apparent Mp = 550,000 designated apolipoprotein B-100 (apo-B-100) and in some LDL preparations, minor components termed apo-B-74 ( M I = 410,000) and apo-B-26145,000).The structural and metabolic relationships among these LDL apoproteins remain obscure.In the present study, we show that the mixing of proteolytic inhibitors with blood at the moment of collection prevents the appearance of apo-B-74 and -26 in plasma LDL indicating that these peptides are derived by proteolytic degradation of apo-B-100.In order to simulate the degradation in vitro, LDL were digested with plasmin, trypsin, chymotrypsin, thrombin, and tissue and plasma kallikreins and the degradation products analyzed by polyacrylamide gradient gel electrophoresis.While plasmin, trypsin, and chymotrypsin caused extensive degradation of apo-B-100, thrombin, and tissue and plasma kallikreins generated limited cleavage patterns.LDL digested with thrombin contained stoichiometric amounts of two peptides with apparent M , = 385,000 and 170,000.Mixing experiments showed that the thrombin-derived peptides of apo-B-100 did not co-migrate with apo-B-74 and B-26 during electrophoresis indicating that these peptides were different.In contrast, LDL digested with kallikrein eontained stoichiometric amounts of two peptides with apparent molecular weights identical to apo-B-74 and -26.Together, the above results indicate that apo-B-74 and -26 are degradation products of apo-B-100 and are not produced by the action of thrombin.Whether the expression of a kallikrein-like activity in vivo accounts for the specific degradation of LDL B-100 to yield LDL B-74 and -26 remains to be determined.Apolipoprotein B is a major protein constituent of chylo-